CSL trials of HDL cholesterol drug to continue

03/26/2007 | Age (Melbourne, Australia), The

Australian biotech CSL Ltd. announced enough success in Phase II trials of its experimental drug CSL-111, designed to cut plaque in heart arteries by raising the levels of "good" cholesterol, to continue development. The trial on 183 Canadians showed no statistically significant reduction of plaque in heart arteries after four treatments.

View Full Article in:

Age (Melbourne, Australia), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR